PT - JOURNAL ARTICLE AU - H.E. Baxendale AU - D. Wells AU - J. Gronlund AU - A. Nadesalingam AU - M. Paloniemi AU - G. Carnell AU - P. Tonks AU - L. Ceron-Gutierrez AU - S. Ebrahimi AU - A. Sayer AU - J.A.G. Briggs AU - X. Xiong AU - J.A. Nathan AU - G.L. Grice AU - L.C. James AU - J. Luptak AU - S. Pai AU - J.L. Heeney AU - R. Doffinger TI - Critical care workers have lower seroprevalence of SARS-CoV-2 IgG compared with non-patient facing staff in first wave of COVID19 AID - 10.1101/2020.11.12.20145318 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.12.20145318 4099 - http://medrxiv.org/content/early/2020/11/13/2020.11.12.20145318.short 4100 - http://medrxiv.org/content/early/2020/11/13/2020.11.12.20145318.full AB - With the first 2020 surge of the COVID-19 pandemic, many health care workers (HCW) were re-deployed to critical care environments to support intensive care teams to look after high numbers of patients with severe COVID-19. There was considerable anxiety of increased risk of COVID19 for staff working in these environments.Using a multiplex platform to assess serum IgG responses to SARS-CoV-2 N, S and RBD proteins, and detailed symptom reporting, we screened over 500 HCW (25% of the total workforce) in a quaternary level hospital to explore the relationship between workplace and evidence of exposure to SARS-CoV-2.Whilst 45% of the cohort reported symptoms that they consider may have represented COVID-19, overall seroprevalence was 14% with anosmia and fever being the most discriminating symptoms for seropositive status. There was a significant difference in seropositive status between staff working in clinical and non-clinical roles (9% patient facing critical care, 15% patient facing non-critical care, 22% nonpatient facing). In the seropositive cohort, symptom severity increased with age for men and not for women. In contrast, there was no relationship between symptom severity and age or sex in the seronegative cohort reporting possible COVID-19 symptoms. Of the 12 staff screened PCR positive (10 symptomatic), 3 showed no evidence of seroconversion in convalescence.Conclusion The current approach to Personal Protective Equipment (PPE) appears highly effective in protecting staff from patient acquired infection in the critical care environment including protecting staff managing interhospital transfers of COVID-19 patients. The relationship between seroconversion and disease severity in different demographics warrants further investigation. Longitudinally paired virological and serological surveillance, with symptom reporting are urgently required to better understand the role of antibody in the outcome of HCW exposure during subsequent waves of COVID-19 in health care environments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: Royal Papworth Hospital NHS Trust: R&D pump priming. This work is now funded by the UKRI and NIHR MC_PC_20016: HICC: Humoral Immune Correlates for COVID19: Defining protective responses and critical readouts for Clinical Trials of Vaccines and Therapeutics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Research Ethics Committee Wales, IRAS: 96194 12/WA/0148. Amendment 5 24.04.2020. All participants provided written, informed consent prior to enrolment in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnalysis code will be made available on an online repository on publication.